目的探讨肺移植治疗终末期肺泡蛋白沉积症的疗效。
方法患者女,55岁,因“胸闷、气喘伴咳嗽6年,加重1年”入院,经反复多次全肺灌洗治疗,效果欠佳,遂行同种异体序贯式双肺移植治疗,观察其临床资料并进行相关文献复习。以“肺移植”和“肺泡蛋白沉积症”为检索词检索中国知网及万方医学网中文文献数据库,以“lung transplantation”及“pulmonary alveolar proteinosis”为检索词检索PubMed数据库,检索时间截止到2022年2月。
结果该患者既往行全肺灌洗19次,前期效果尚可,后期症状进行性加重,粒细胞-巨噬细胞集落刺激因子雾化吸入治疗后,出现过敏反应,胸部CT提示肺部病变逐渐加重。2022年2月15日行肺移植术,PaO 2从47 mmHg(1 mmHg=0.133 kPa)上升到85 mmHg,可脱离吸氧活动,2022年3月2日出院,随访病情稳定。文献检索获得相关英文文献13篇,其中论著2篇,病例报告11篇;肺移植后继发肺泡蛋白沉积症9篇;肺移植治疗肺泡蛋白沉积症4篇,报道了3个病例;国内未见肺移植治疗肺泡蛋白沉积症的报道。
结论肺移植治疗终末期肺泡蛋白沉积症,早期安全有效,长期效果有待进一步观察。
ObjectiveTo observe the efficacy of lung transplantation for pulmonary alveolar proteinosis (PAP) patients and to improve the understanding of the therapy.
MethodsThe clinical data of a patient with autoimmune PAP treated with sequential homogenous bilateral lung transplantation were described and the literatures were reviewed.
ResultsThis 55-year-old female patient was diagnosed with autoimmune PAP and had been treated with whole lung lavage for 19 times, but only achieved short-term symptomatic relief after each operation. Inhalation of granulocyte macrophage colony stimulating factor occurred allergic reactions. Lung transplantation was performed on February 15, 2022, and a significant improvement in oxygenation and clinical symptoms were observed. The patient remained stable during follow-up.
ConclusionTreatment with lung transplantation is safe and effective for end-stage patients with PAP in the early phase, but the long-term effect remains to be observed.
王跃斌,李丰科,丁志丹,等. 肺移植治疗肺泡蛋白沉积症1例并文献复习[J]. 中华结核和呼吸杂志,2022,45(07):667-670.
DOI:10.3760/cma.j.cn112147-20220302-00165版权归中华医学会所有。
未经授权,不得转载、摘编本刊文章,不得使用本刊的版式设计。
除非特别声明,本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。
王跃斌:酝酿和设计实验、实施研究、采集、分析并解释数据、起草文章、统计分析、对文章的知识性内容作批评性审阅、支持性贡献;李丰科:实施研究、采集、分析并解释数据;丁志丹:实施研究、采集数据;赵凯、方泽民:实施研究;冯敏:实施研究、对文章的知识性内容作批评性审阅;常思远、金峰、黄明君:实施研究;赵高峰:酝酿和设计实验、实施研究、对文章的知识性内容作批评性审阅、指导、支持性贡献
王跃斌, 李丰科, 丁志丹, 等. 肺移植治疗肺泡蛋白沉积症1例并文献复习[J]. 中华结核和呼吸杂志, 2022, 45(7): 667-670. DOI: 10.3760/cma.j.cn112147-20220302-00165.

你好,我可以帮助您更好的了解本文,请向我提问您关注的问题。